Cancer treatment centers across India are currently experiencing a critical shortage of two widely used chemotherapy medications: cisplatin and carboplatin. This scarcity is raising significant concerns among oncologists about potential disruptions to patient care, particularly for those battling common cancers.
The Critical Role of Cisplatin and Carboplatin
Cisplatin and carboplatin are foundational drugs in the treatment of numerous malignancies, including cancers of the lung, head and neck, cervix, ovary, bladder, and testis. For many patients, these platinum-based agents are considered the standard of care and are often administered with curative intent.
Dr. Niti Raizada, Principal Director of Medical Oncology at Fortis Hospitals, Bengaluru, emphasized their importance: "These medicines are used with a cure-driven intent, so they play a crucial role in improving survival and overall treatment outcomes." Similarly, Dr. Vijay Patil, Consultant Medical Oncology at P. D. Hinduja Hospital, Mumbai, highlighted their critical role in head and neck, cervical, testicular, ovarian, and lung cancers.
Impact on Patients and Treatment Protocols
The immediate impact of this shortage falls heavily on patients currently undergoing chemotherapy, newly diagnosed individuals, and those requiring concurrent chemotherapy and radiation. Cancer treatment regimens are meticulously planned, and the limited availability of these drugs may force hospitals to either delay cycles or consider alternative protocols.
However, as Dr. Raizada noted, "Alternatives may not always offer the same level of evidence or suitability as the standard platinum-based protocol." Such disruptions can cause immense anxiety for both patients and their clinicians, especially when treatment is aimed at a cure.
Understanding the Supply Chain Crisis
Several factors are contributing to this alarming situation:
- Rising Platinum Prices: Platinum, a key component in the active pharmaceutical ingredients (APIs) of these drugs, has seen a sharp increase in global market prices.
- Supply Chain Challenges: Disruptions in the global supply chain are affecting the availability of raw materials.
- Price Controls: Existing price control mechanisms on older, generic cancer drugs mean that manufacturers face increased production costs without the ability to adjust selling prices, making production less viable.
Rajiv Singhal, General Secretary of the All India Organisation of Chemists & Druggists (AIOCD), confirmed that "the active pharmaceutical ingredient (API) used in these drugs is derived from platinum, the availability of which has been affected by movements in global precious metal markets." He added that while manufacturers are striving to procure raw materials, supplies have been impacted over the past three months.
Government and Industry Response
The Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, is aware of the situation. Secretary Manoj Joshi stated that the government is "looking into it and will take a decision on the matter soon."
Meanwhile, senior oncologists like Dr. Shyam Aggarwal, Chairman of Medical Oncology at Sir Ganga Ram Hospital, have publicly urged government intervention, highlighting the struggles patients face in accessing these essential medicines. Hospitals are actively monitoring inventories and exploring alternative procurement channels to minimize patient impact.
With India reporting approximately 1.4 million new cancer cases annually, and platinum-based chemotherapy remaining a cornerstone of treatment for many common cancers, resolving this shortage is a matter of urgent public health concern.